ARCT logo

Arcturus Therapeutics Holdings Inc. Stock Price

NasdaqGM:ARCT Community·US$237.6m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 72 Fair Values set on narratives written by author

ARCT Share Price Performance

US$8.46
-1.72 (-16.90%)
US$54.97
Fair Value
US$8.46
-1.72 (-16.90%)
84.6% undervalued intrinsic discount
US$54.97
Fair Value
Price US$8.46
AnalystHighTarget US$54.97
AnalystLowTarget US$8.00

ARCT Community Narratives

AnalystHighTarget·
Fair Value US$54.97 84.6% undervalued intrinsic discount

Self-amplifying mRNA Will Meet Aging Global Therapy Demand

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value US$8 5.8% overvalued intrinsic discount

Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$8
5.8% overvalued intrinsic discount
Profit Margin
14.76%
Future PE
158x
Price in 2029
US$9.66

Trending Discussion

Updated Narratives

ARCT logo

ARCT: Fair Value View Balances Execution Concerns With Pipeline Progress

Fair Value: US$8 5.8% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ARCT logo

ARCT: CF And OTCD mRNA Pipeline Progress Will Drive Future Upside

Fair Value: US$54.97 84.6% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

1 Risk
2 Rewards

Arcturus Therapeutics Holdings Inc. Key Details

US$82.0m

Revenue

US$112.2m

Cost of Revenue

-US$30.2m

Gross Profit

US$35.6m

Other Expenses

-US$65.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-2.31
-36.79%
-80.19%
0%
View Full Analysis

About ARCT

Founded
2013
Employees
109
CEO
Joseph Payne
WebsiteView website
arcturusrx.com

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Recent ARCT News & Updates

Recent updates

No updates